Showing 8911-8920 of 18111 results for "".
- FDA Expands Sotatercept Indication for PAH: A Closer Look at Clinical Impactshttps://reachmd.com/news/fda-expands-sotatercept-indication-for-pah-a-closer-look-at-clinical-impacts/2484099/The U.S. Food and Drug Administration (FDA) has approved an expanded indication for WINREVAIR™ (sotatercept-csrk), offering new hope for adults with pulmonary arterial hypertension (PAH, WHO Group 1) at high risk for clinical worsening.
- Music Engagement and Cognitive Health: Insights from a 10,800-Participant Studyhttps://reachmd.com/news/music-engagement-and-cognitive-health-insights-from-a-10800-participant-study/2484103/Monash University analysis of 10,893 adults aged ≥70 found routine music engagement was linked to substantially lower dementia incidence—39% lower for always-listening and 35% lower for instrument players. According to
- Advancements in Image-Guided Bleomycin Electrosclerotherapy for Vascular Anomalieshttps://reachmd.com/news/advancements-in-image-guided-bleomycin-electrosclerotherapy-for-vascular-anomalies/2484107/Bleomycin electrosclerotherapy (BEST) is a validated, minimally invasive option for treatment‑resistant vascular anomalies, offering improved lesion reduction with an acceptable safety profile, according to a recent review in
- Emerging Sensor Technologies in Gastrointestinal Diagnostics: Spotlight on Ingestible Capsuleshttps://reachmd.com/news/emerging-sensor-technologies-in-gastrointestinal-diagnostics-spotlight-on-ingestible-capsules/2484114/The FireFLI capsule, a firefly-inspired ingestible biosensor, could enable earlier, noninvasive detection of intestinal inflammation and ischemia—potentially shifting time-to-diagnosis for conditions often recognized too late. According to
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://reachmd.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://reachmd.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://reachmd.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- Exploring Epigenetic Mechanisms in Asthma Recurrence: The Role of Brg1 in ILC2 Regulationhttps://reachmd.com/news/exploring-epigenetic-mechanisms-in-asthma-recurrence-the-role-of-brg1-in-ilc2-regulation/2484071/According to a report, preclinical researchers identify the chromatin remodeler Brg1 (Smarca4) as a central regulator of Group
- Demographic Considerations in Diagnosing Interstitial Ectopic Pregnancyhttps://reachmd.com/news/demographic-considerations-in-diagnosing-interstitial-ectopic-pregnancy/2484074/A new retrospective study out of Boston Medical Center has shed light on a persistent diagnostic challenge in reproductive medicine: the misdiagnosis of interstitial ectopic pregna
- Examining Nerandomilast Efficacy in Idiopathic Pulmonary Fibrosis: Insights from CHEST 2025https://reachmd.com/news/examining-nerandomilast-efficacy-in-idiopathic-pulmonary-fibrosis-insights-from-chest-2025/2484078/Nerandomilast (Jascayd) slowed forced vital capacity (FVC) decline over 52 weeks in the FIBRONEER‑IPF Phase 3 trial